A move to offer costly weight-loss drugs for obese Americans on Medicare and Medicaid may be in the works, but such a program may run into problems with voluntary participation and expense concerns.

Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach ...

A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.

Gov. Phil Murphy's ideas to cut $100 million from the State Health Benefits Program include charging higher co-pays and ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

Medical professionals observe that GLP-1 medications like Ozempic show promise for treating rheumatoid arthritis alongside other inflammatory conditions.

SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.

Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs ...

Empaveli approved to treat two rare kidney diseases; Elevidys available again for ambulatory patients; Mounjaro shows benefit in cardiovascular disease; ...

A doctor has issued a warning to people who use weight loss jabs over the 'golden dose'. The use of GLP-1 medication, such as ...

A trial investigating the ability of Eli Lilly’s Mounjaro (tirzepatide) to reduce the risk of cardiovascular issues has met ...

The Trump administration outlines a plan to cover weight-loss drugs under Medicare and Medicaid, allowing certain state ...